6/28/23, 11:40 PM IVERCOR-COVID19 Pathway Feedback Search Clinical Topics Home Studies IVERCOR COVID19 IVERCOR COVID19 Disease COVID 19 infection Trial question What is the role of ivermectin in patients with COVID-19 infection? Study design Multi-center Double blinded RCT Population Characteristics of study participants 47.0% female N = 501 53.0% male 501 patients (237 female, 264 male) Inclusion criteria: adult outpatients with COVID-19 positive nasal swabs within 48 hours Key exclusion criteria: current home oxygen use, hospitalization requirement for COVID-19 at the time of diagnosis, or a history of hospitalization for COVID-19 Interventions N=250 ivermectin (a total dosage of 24-48 mg PO, based on weight) N=251 placebo (equivalent number of matching placebo tablets) Primary outcome Hospitalization 8.4 % 8.4 6.3 % 5.6 4 2 % https://web.pathway.md/studies/recE7uqddZTxCQYtm 1/2 6/28/23, 11:40 PM IVERCOR-COVID19 Pathway 4.2 % 2.1 % No significant difference 0.0 % Ivermectin Placebo No significant difference in hospitalization (5.6% vs. 8.4%; OR 0.65, 95% CI 0.32 to 1.31) Secondary outcomes No significant difference in death from all causes (1.6% vs. 1.2%; OR 1.34, 95% CI 0.3 to 6.07) No significant difference in invasive mechanical ventilation (1.6% vs. 1.2%; OR 1.34, 95% CI 0.3 to 6.07) No significant difference in dialysis (0.4% vs. 0.4%; OR 1, 95% CI 0.06 to 16.14) Safety outcomes No significant differences in dialysis, adverse events, or death from all causes. Significant difference in time to invasive mechanical ventilation (5.25 days vs. 10 days). Conclusion In adult outpatients with COVID-19 positive nasal swabs within 48 hours, ivermectin was not superior to placebo with respect to hospitalization. Reference Julio Vallejos, Rodrigo Zoni, Mar a Bangher et al. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial. BMC Infect Dis. 2021 Jul 2;21(1):635. Open reference URL https://web.pathway.md/studies/recE7uqddZTxCQYtm 2/2